

/ / : // :

Quality assessment of glucosamine preparations available in drug market of Iran

Nemati M.^{1,2*}, Valizadeh H.¹, Ansarin M.², Ghaderi F.¹

¹Faculty of Pharmacy, Tabriz University of Medical Sciences, ²Drug Applied Research Center, Tabriz University of Medical Sciences

Received: 2006/6/21, Accepted: 2007/2/1

Objectives: the purpose of this study was the evaluation of pharmaceutical properties and quality control of glucosamine preparations available in Iran drug market. **Methods:** 10 commercial products were selected and evaluated for some Pharmaceutical characteristics such as content uniformity, assay, weight variation and dissolution test. Determination of glucosamine was performed according to a new high performance liquid chromatography (HPLC) method developed for the first time. The method was based on pre column derivatization of glucosamine by orthophthaldialdehyde (OPA). **Results:** the results of these tests about 10 commercial products were as follow: assay was between 13.69% and 138.72%, for content uniformity RSD% was between 4.17 and 26.60, weight variation had RSD% between 0.69 and 7.5. Dissolved glucosamine (%) in dissolution test was between 20.03% and 98.71%. Similarity factor test on the results of dissolution test showed that at least 3 commercial products have not been in an acceptable range in comparison with reference product (No.2). **Conclusion:** according to these results, good controls on the quality of food supplements are required.

Key words: Glucosamine, Pharmaceuticals, quality control.

/ / : // :
 (Similarity factor) % / % /
 % / % /
 ()

*Corresponding Author: Dr Mahboob Nemati, Assistant Professor, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tel: 0411-3372250; Fax: 0411-3344798; E-mail: nematim@tbzmed.ac.ir

HPLC
() (FMOOC) ()
() ()

HPTLC ()
LC-MS ()
()

HPLC
(OPA)

()

C, D, E

Nutripharmaceuticals

()

FLUKA
(pH 9.5 /) Sigma
(pH 6.5

.Merck

()

(KNAUER) HPLC
BECKMAN RF-551
0.0001 GR200 AND

HPLC

(Weight variation)

()

USP29

A % (Assay) :
B % Assay

() ()
/ Eurochrom 2000

()

mg/L rpm


(Content Uniformity) :

(assay)

/ /
/ /

() USP I :
rpm (ml)


HPLC



HPLC

(OPA)

OPA .



OPA

()

Spherimage 80 ODS2 (250x4 mm)

Knauer

OPA :

A

B

Product No.	Dosage form	Label information on active ingredients (mg)
C1	capsule	Glucosamine Hydrochloride (500), Chondroitin sulfate (400)
C2	capsule	glucosamine sulfate (500)
C3	capsule	Glucosamine sulfate (500)
C4	tablet	Glucosamine sulfate KCl (500)
C5	capsule	Glucosamine sulfate (500)
C6	tablet	Glucosamine Hydrochloride (500), Chondroitin sulfate (400)
C7	tablet	Glucosamine sulfate KCl (750) MSM (200)
C8	capsule	Glucosamine sulfate (500)
C9	capsule	Glucosamine sulfate (500) Chondroitin sulfate (400)
C10	capsule	Glucosamine sulfate (750)

Product No.	Assay		Content uniformity			Weight variation	
	(mg)	(%)	(mg)	%	RSD%	Mean (n=20)	RSD%
C1	513.77	102.75	449.22	89.84	17.62	0.96	3.91
C2	564.34	112.87	556.83	111.36	4.60	0.66	3.49
C3	436.45	87.29	500.70	100.14	4.17	0.53	3.79
C4	544.45	108.90	617.88	123.57	23.15	1.09	1.28
C5	481.80	96.36	605.20	121.04	16.04	1.06	7.53
C6	693.60	138.72	702.54	140.50	8.21	1.16	0.69
C7	593.12	79.08	829.93	110.65	26.60	1.22	1.07
C8	199.82	39.96	261.65	52.33	21.53	0.67	2.48
C9	141.40	28.27	123.60	24.72	13.99	0.95	2.51
C10	102.71	13.69	73.96	9.86	15.56	0.71	3.20

(A % / % / / / (RSD%)

.()



)

) (% /

(%

(/)

(/)



OPA

HPLC

FDA

.A)

.B)

7- References:

1. Hauselman H.J., Nutripharmaceuticals for osteoarthritis, Best practice & research in clinical rheumatology, 2001, 15: 595-607.
2. Ishiguro N., Kojima T., Poole A.R., Mechanism of cartilage destruction in osteoarthritis Nagoya J Med Sci 2002, 65: 73-84.
3. Todd C., Meeting the therapeutic challenge of the patient with osteoarthritis., J Am Pharm Assoc (Wash). 2002, 42: 74-82.
4. Da Camara C.C., Dowless, G.V., Glucosamine sulfate for osteoarthritis. Ann Pharmacother, 1998, 32: 580-7.
5. AbdelFattah W., Hammad T., Chondroitin sulfate and glucosamine: a review of their safety profile. JANA 2001, 3: 16-23.
6. Kelly G.S. the role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev., 1998, 3, 27-39.
7. Ziqi Zhou J., Waszkuc T., Felicia M. Determination of Glucosamine in Raw Materials and Dietary Supplements Containing Glucosamine Sulfate and/or Glucosamine Hydrochloride by High-Performance Liquid Chromatography with

-
- FMOc-Su Derivatization: Collaborative Study J. AOAC Int, 2005, 88: 1048 – 1058.
8. David J.I., Zhang L., Chen J., Peng E., Precolumn Derivatization Liquid Chromatography Method for Analysis of Dietary Supplements for Glucosamine: Single Laboratory Validation Study, J. AOAC Int, 2005, 88: 413 – 417.
 9. Liang Z., Leslie J., Adebawale A., Ashraf M., Edington A. D., Determination of the Nutraceutical, glucosamine hydrochloride, in raw material, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC. J. Pharm. Biomed. Anal, 1999, 20: 807-814.
 10. Aghazadeh-Habashi A., Sattari S., Pasutto F., Jamali F., High Performance Liquid Chromatographic Determination of Glucosamine in Rat Plasma, J Pharm Pharmaceut Sci, 2002, 2: 176-180.
 11. Wu Y., Hussain M., Fassihi R., Development of a simple analytical methodology for determination of glucosamine release from modified release matrix tablets, J. Pharm. Biomed. Anal. 2005, 38: 263–269.
 12. Udayan D., Joel A.D., Capillary electrophoretic analysis of advanced glycation endproducts formed from the reaction of reducing sugars with the amino group of glucosamine, Analytical Biochemistry, 2005, 343: 237-243.
 13. Sullivan C., Sherma J., Development and validation of an HPTLC- Densitometry method for assay of glucosamine of different forms in dietary supplement tablets and capsules, Acta Chromatographica, 2005, 15: 119-30.
 14. Persiani S., Roda E., Rovati L.C., Locatelli M., Giacovelli G., Roda A., Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man, Osteoarthritis and Cartilage, 2005, 13: 1041-9.
 15. Nemati M., Oveisi M., Abdollahi H., Sabzevari O., Differentiation of bovine and porcine gelatins using principal component analysis, J. Pharm. Biomed. Anal, 2004, 34: 485–492.
 16. Kamp, R.M, in: Protein Structure Analysis, Kamp, R.M., Choli-Papadopoulou, T., Wittmann-Liebold, B., (Eds.), Springer, Berlin, 1997, 231–248.
 17. Nemati M., Valizadeh H., Ansarin M., Ghaderi F., Development of a simple and sensitive HPLC method for determination of glucosamine in pharmaceutical formulations, J. AOAC Int., (In press).

Archive of SID